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EDITORIAL 
 
 
What do scores mean?  Informed interpretation and clinical judgement are needed 
 
 
Measurement is the essential heart of high quality daily practice and clinical research. 
Measurement is essential to assess or monitor our patients, and to deliver evidence-based 
medicine.  Measurement usually generates scores.  But what do scores mean, how can 
informed judgements be based on them, and how can they be appropriately used in the 
clinic, in research and by licensing authorities? 
 
An article1 in this month’s BJD addresses one “scoring” issue arising from the use of the 
DLQI, but in so doing raises a range of dilemmas of relevance to all clinical scoring.   Rencz et 
al1 note that if a patient with psoriasis answers “not relevant” to one or more of the ten 
DLQI questions, say concerning sport, but actually can’t do this activity because their 
psoriasis is so severe, their DLQI score may not reach a guideline threshold for biologic 
therapy (i.e. 10). They propose a formula to adjust the score upwards, based on the 
responses to the other questions. The application of the formula to a real data set revealed 
that when the formula was applied to 242 psoriasis patients, 8 more (3.3%) reached the 
threshold of DLQI score 10.1 
 
There is no measurement that is ‘absolute’.  Even data describing, say, length (where a 
meter is defined as the distance light travels in 1 / 299,792,458 sec)2 may be influenced by 
the measurement instrument or observer: clinical data always involves a range of 
confounding factors. The observer, the measurement device and the patient herself all have 
unpredictable variability. Clinicians are familiar with concepts of false positive or false 
negative results and many techniques are used to reduce the impact of this variability in 
research. But problems arise when the confidence that we place on data with which we are 
familiar, such as measurement of height, is unthinkingly or inappropriately applied to clinical 
data with its inherent variability and unfamiliar meaning. 
 
Clinicians learn to interpret clinical scores from published “normal” score ranges, from 
guidelines and from an unclear osmosis of clinical experience. However, population norms 
may not be applicable to a specific individual patient, and then in many common situations 
clinicians may interpret data in different ways, as highlighted by the debate about 
interpretation of blood pressure values and when therapy should be introduced.3 But how 
can we interpret a quality of life score and whether its change over time is significant?  In 
order to give clinically useful meaning to quality of life scores, it is possible to define score 
band descriptors.4   But bands, however well validated, apply artificial steps to what is 
usually a smooth continuum.  So the clinical situation reflected by the close scores 
immediately on either side of a band dividing point is similar, though by falling into two 
bands the band description differs. In order to define when the change in a score becomes 
“significant” to a patient, the Minimal Important Clinical Difference (MCID) can be 
calculated.5,6   But, again, this concept needs to be interpreted with caution. For example, 
the MCID may in reality be a much smaller score change at the lower end of a score 
spectrum than at the higher end, even though the user is presented with a single figure 
apparently to be applied across the range.   
 
So where does this leave the even more confused clinician?  The good news is that this leads 
directly to an affirmation of the value and central place of clinical judgement and wisdom, 
our special and unique clinical skills.  While agreeing with Rencz et al1   that there may be an 
issue, perhaps the real problem lies with the guidelines and authorities who may ignore the 
limits of clinical measurement. What matters is that scores should guide (not mandate) 
clinical decisions, and that the clinician should be free to use scores within their wider 
knowledge of what is best for an individual patient. 
 
During the development of the DLQI7 in the early 1990s, various scoring methods were 
considered, including that currently proposed by Rencz et al.1   We decided against 
suggesting this adjustment formula because we felt that in a busy clinical setting it would be 
too complicated for a clinician to calculate the total score. Moreover, a question marked 
“not relevant” could reflect genuine lack of relevance and correspond to a real zero score, 
since the patient might be not interested in an activity such as sport, even when fully 
healthy.   
 
Since then all of the validation and use of the DLQI, reported in thousands of articles, has 
been based on the simple standard scoring system of adding the individual question scores. 
Before using the proposed score adjustment formula clinically or in research, a repeat 
extensive process of validation would have to be carried out. For example, a new score band 
descriptor study would need to be undertaken, rather than applying the current bands. And 
applying the proposed formula would most likely cause confusion especially when 
comparing new studies with the old ones where the first score calculation was used. 
 
So how did the situation arise whereby clinicians may be required to apply a sharp cut-off to 
a continuum of clinical scores? To try to alter attitudes to the value of considering quality of 
life, and to subconsciously educate clinicians, a simple message was required.8   Hence the 
proposal that it might be possible to define current severe psoriasis as PASI>10, BSA>10 or 
DLQI>10 (the “Rule of Tens”).9   This was always an approximation, based on three inexact 
measurements.  But mandating clinicians to interpret this in an absolute way ignores the 
reality faced by clinicians daily. Whatever formula is used to calculate DLQI scores, they 
should be used to help the clinician take the most appropriate decision for individual 
patients, not used to restrict clinical judgement.  
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